Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIG-T thromboprophylaxis trial in advanced germ cell tumors
2022-502426-41-00Phase 3Authorised
- Sponsor
- Gustave Roussy
- Start
- Oct 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of enoxaparin, dalteparin and tinzaparin in germ cell tumor (GCT) (3 arms), sponsored by Gustave Roussy. Primary endpoint: Proportion with thromboembolic event. Planned start Oct 2023; status: authorised.
02
Drugs
enoxaparindalteparintinzaparin
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on 2022-502426-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502426-41-00.